Specific proteins of inflammatory cells and alpha1-proteinase inhibitor in alveolar epithelial lining fluid of polytraumatized patients by Jochum, Marianne
J. A. Sturm (Ed.) 
Adult Respiratory 
Distress Syndrome 
An Aspect of Multiple Organ Failure 
Results of a Prospective Clinical Study 
Contributors 
H . Bartels · Μ. Behrmann · U. Böhme · J. Bruch 
Η . Creutzig · A . Dwenger · M . Funck · R. Funk · K.F. Gratz 
M . Jochum · E. Jonas · Th. Joka · C.-J. Kant * M . Kirschfink 
J. Knöller · W. König · Ε. Kreuzfelder · U. Lehmann 
J. Lindena · Β. Lueken · W. Machleidt · M . Maghsudi 
J. Mirkhani * M . L . Nerlich · H . Neuhof · B. Neumann 
C. Neumann · U. Obertacke · H.-J. Oestern · H.-C. Pape 
U. Pison · T. Pohlemann · Ε. Reale · G. Regel · Μ. Reuter 
G. Röllig · U. Rother · K. R Schmit-Neuerburg 
W. Schönfeld · W. Schramm · G. Schweitzer · W. Seeger 
A . Seekamp · J. Seidel · M . Spannagl · W. Stangel 
J.A. Sturm · N . Suttorp · O. Thraenhart · H . Tscherne 
D. H . Wisner · G. Zilow 
Wi th 178 Figures 
Springer-Verlag 
Berlin Heidelberg New York London Paris 
Tokyo Hong Kong Barcelona Budapest 
Contents 
Introduction 
J . A . S T U R M . With 3 Figures 1 
I Clinical Aspects 
Study Protocol 
H.-C. P A P E and C.-J. K A N T 7 
Extravascular Lung Water: Clinical Methodology 
A. S E E K A M P , U. O B E R T A C K E , and J . A . S T U R M 
With 1 Figure 11 
Bronchoalveolar Lavage 
U. O B E R T A C K E , Τ Η . J O K A , Μ. R E U T E R , and 
K . P . S C H M I T - N E U E R B U R G . Wi th 1 Figure 17 
Morphometric Description of the Study Population 
T H . J O K A , J . A . S T U R M , U. O B E R T A C K E , and G. R E G E L . 2 2 
Development of a Linear Scoring System 
U. O B E R T A C K E , T H . J O K A , and C. N E U M A N N 
With 4 Figures 25 
Clinical Definition of ARDS 
An Index Based on Bedside-Derived Parameters 
C. N E U M A N N , J . A . S T U R M , and G. R E G E L 
With 1 Figure 30 
Treatment and Clinical Course 
T H . J O K A , U. O B E R T A C K E , J . A . S T U R M , and 
M . L . N E R L I C H . With 10 Figures 34 
VI Contents 
Progressive Organ Failure 
M . L . N E R L I C H . Wi th 17 Figures 45 
I I Activation of Humeral Cascade Systems 
Adult Respiratory Distress Syndrome and Complement: 
Significance of C3a in Diagnosis and Prognosis 
G . Z I L O W , U . R O T H E R , and M . K I R S C H F I N K 
With 6 Figures 59 
Differences in Activation of Coagulation and Fibrinolysis 
After Polytrauma with Respect to the Development 
of Adult Respiratory Distress Syndrome 
W. S C H R A M M and M . SPANNAGL . With 7 Figures 75 
I I I Activation of Cellular Systems 
Nonspecific Immune System, Plasma Proteins 
and Characteristics of the Erythrocyte Insulin Receptor 
A. D W E N G E R , G . R E G E L , G . S C H W E I T Z E R , G . R Ö L L I G , 
and J . L I N D E N A . Wi th 16 Figures 91 
Morphological and Functional Changes of Alveolar Cells 
T H . J O K A , U . O B E R T A C K E , J . B R U C H , Μ . R E U T E R , and 
K . P . S C H M I T - N E U E R B U R G 128 
Functional Changes in Polymorphonuclear Leukocyte 
Function Following Severe Polytraumatization 
J . S E I D E L , J . M I R K H A N I , M . B E H R M A N N , and 
W. S T A N G E L . With 18 Figures 135 
Changes in Reticuloendothelial Capacity 
Associated with Liver Dysfunction in Multiple Trauma 
G . R E G E L , K . F . G R A T Z , T. P O H L E M A N N , J . A . S T U R M , 
and H . T S C H E R N E . With 5 Figures 156 
CD3 + , CD4 + , C D 8 + and Β Lymphocyte Numbers 
in Blood and Bronchoalveolar Lavage Fluid 
from Trauma Patients with and without ARDS 
E. K R E U Z F E L D E R , Μ . M A G H S U D I , R. F U N K , and 
O. T H R A E N H A R T . Wi th 1 Figure 168 
Contents VII 
IV Activation of Inflammatory Cells 
Role of Leukotrienes in the Pathophysiology of ARDS 
After Polytrauma 
J . K N Ö L L E R , W. S C H Ö N F E L D , and W. K Ö N I G 
With 8 Figures 177 
Specific Proteins of Inflammatory Cells 
and a rProteinase Inhibitor in Alveolar Epithelial 
Lining Fluid of Polytraumatized Patients: 
Do They Indicate Posttraumatic Lung Failure? 
M . J O C H U M . With experimental data from A. D W E N G E R 
and W. M A C H L E I D T . Wi th 9 Figures 193 
V Endothelial and Epithelial Mechanisms of Injury 
Plasma and Bronchoalveolar Lavage Fluid Proteins 
as Markers of Increased Lung Permeability in ARDS 
as a Result of Multiple Trauma 
A. D W E N G E R , G. S C H W E I T Z E R , and M . F U N C K 
With 13 Figures 215 
Lung Capillary Leak After Severe Trauma: 
A Prospective Clinical Study 
J . A . S T U R M , D . H . W I S N E R , H . - J . O E S T E R N , C.-J. K A N T , 
H . T S C H E R N E , H . -C . P A P E , U. L E H M A N N , and 
H . C R E U T Z I G . Wi th 10 Figures 230 
Alveolar Surfactant Function in Severely Injured Patients 
W. S E E G E R , U. P I S O N , T H . J O K A , and H . N E U H O F 
With 5 Figures 245 
Adult Respiratory Distress Syndrome as a Manifestation 
of a General Permeability Defect 
E. K R E U Z F E L D E R , U. O B E R T A C K E , B. N E U M A N N , and 
O. T H R A E N H A R T . Wi th 7 Figures 257 
Early and Late Ultrastructural Changes in the Lungs 
of Patients Suffering from Severe Polytrauma 
H . B A R T E L S and E. R E A L E . With 13 Figures 265 
V I I I Contents 
V I Experimental Studies 
Simultaneous Measurement of Endothelial Cell Damage, 
Elastase Release, and Chemiluminescence Response 
During Interaction Between 
Polymorphonuclear Leukocytes and Endothelial Cells 
E. JONAS , A . D W E N G E R , B. L U E K E N , and U. B Ö H M E 
With 3 Figures 281 
Influence of Short- and Long-Term 
Endotoxin Administration on the Phagocytic Functions 
of Polymorphonuclear Leukocytes 
and Reticuloendothelial System in a Sheep Model 
G. R E G E L , A . D W E N G E R , G. S C H W E I T Z E R , A . S E E K A M P , 
and J . A . S T U R M . Wi th 6 Figures 294 
The Three-Compartment Model in Sheep: 
The Effect of Recurrent Endotoxemia on Endothelial 
and Epithelial Permeability in the Lung 
A . S E E K A M P , A . D W E N G E R , G. R E G E L , and J . A . S T U R M 
With 7 Figures 308 
Bacterial Toxins and Terminal Complement Complex: 
Significance for Lung Microvascular Injury 
W. S E E G E R , Ν . S U T T O R P , and H . N E U H O F 
With 7 Figures 321 
Subject Index 341 
Specific Proteins of Inflammatory Cells 
and <*!-Proteinase Inhibitor in Alveolar Epithelial 
Lining Fluid of Polytraumatized Patients: 
Do They Indicate Posttraumatic Lung Failure? 
M . J O C H U M 1 
With experimental data from A . D W E N G E R 2 and W. M A C H L E I D T 
Introduction 
Despite numerous hints that activated inflammatory cells may trigger lung 
injury, the causative role especially of the polymorphonuclear (PMN) 
granulocytes (neutrophils) to promote enhanced microvascular permeability 
in acute respiratory distress syndrome (ARDS) is still a matter of debate [22, 
25, 27, 28, 31]. In the early 1980s, Hammerschmidt et al. [11] demonstrated 
that complement-mediated neutrophil sequestration in pulmonary capillaries 
leading to lung vascular endothelial injury was a common feature of patients 
suffering from acute respiratory distress syndrome (ARDS) . Meanwhile, 
however, a wealth of basic information exists indicating that neutrophil 
activation occurs to a similar extent in high-risk patients who do not, how-
ever, eventually develop ARDS [21]. Moreover, signs of ARDS have been 
described in neutropenic patients, thus calling into question whether neutro-
phils are required in the generation of ARDS [19]. Yet, the latter observa-
tions may be taken as an indirect evidence for the importance of other 
inflammatory cells, e.g., activated alveolar macrophages [7], in disturbing 
the alveolar barrier from the epithelial side of the alveoli, at least in neutro-
penic patients. 
Although the primary role of both types of phagocytes (invading neutro-
phils, sessile lung macrophages) in the development of ARDS still deserves 
further clarification, the potentially harmful armament of these cells released 
during cell activation in response to an inflammatory event (e.g., multiple 
trauma) is beyond doubt. This potent cellular equipment for causing tissue 
injury in the microenvironment of the phagocytes include elastolytic 
proteinases (e.g., neutrophil elastase, macrophage-derived cathepsin B) and 
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highly destructive oxygen species [7, 18]. The production of the most effective 
molecules of the latter - hypochlorous acid, chloramines and hydroxyl 
radicals - is greatly enhanced during phagocytosis by the catalytic action of 
the neutrophil lysosomal proteins, myeloperoxidase [18] and lactoferrin [17]. 
Moreover, extracellularly released lactoferrin is known to increase the 
adhesiveness of neutrophils to pulmonary endothelial cells, thereby prolong­
ing the destructive action of the phagocytes on the vascular permeability 
barrier [30]. 
The harmful efficacy of proteolytic and oxidative substances discharged 
to the extracellular milieu is normally restricted to and abolished in the close 
vicinity of phagocytizing cells by numerous proteinase inhibitors [29] and 
antioxidants [20]. During an overshooting activation process, e.g., caused by 
a serious trauma event, the local anti-oxidative capacity seems to be 
overcome, especially in the lung, thereby enabling also the oxidative 
inactivation of proteinase inhibitors [29]. In this respect α!-proteinase 
inhibitor (c^PI), by far the most effective inhibitor of the neutrophil serine 
proteinase elastase, is highly sensitive to oxidative destruction [29, 18]. In 
addition, this inhibitor molecule can easily be degraded by cysteine 
proteinases (cathepsin B , L) and a metalloproteinase released from activated 
alveolar macrophages [29]. Just recently, the proteolytic inactivation of ciiPI 
by a neutrophil metalloproteinase has been also demonstrated [8]. Interes­
tingly, the ajPI , which is probably degraded proteolytically in the epithelial 
lining fluid (ELF) of the lung, is inactive against elastase [26, 32], but has 
proved to be a potent neutrophil chemoattractant [4] and may thus augment 
the elastase burden of the lung during an inflammatory process. 
The increase of the lung's permeability due to the proteolytic/oxidative 
destruction of the endothelial-epithelial barrier in the early phase of A R D S is 
characterized by the influx of plasma proteins into the ELF [12]. Whereas this 
stage of the disease may be reversible, the later fibrotic phase [3] is often 
associated with a lethal outcome due to an irreversible gas exchange 
disturbance. As shown recently, activated lung macrophages seem to play an 
essential role in stimulating fibroblasts to enhanced collagen synthesis via the 
production of a platelet-derived growth factor-like substance [5]. In addition, 
the diminished regulatory function of destroyed alveolar epithelial cells also 
promotes fibroblast activity and, thus, fibrosis [1]. The extracellular occurr­
ence of the procollagen-III-peptide (P-III-P) in the ELF can be taken as a 
clear indication of such an intensified fibrotic process [6]. 
Up to now, the evaluation of biochemical changes in the ELF drawn by 
the broncho-alveolar lavage ( B A L ) technique [24] has been widely applied to 
gain more insight into the pathomechanisms taking place during lower 
respiratory tract inflammation [10, 13, 25, 26, 31, 32]. However, convincing 
clarification of the significance of the different biochemical factors under 
discussion as inflammatory mediators has been hampered by the lack of 
close-meshed follow-up determinations after an event (multiple injuries, 
septicemia, etc.) which suddenly renders a person a high-risk ARDS patient. 
Therefore, the aims of our present study were as follows: 
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- Firstly, to find out whether daily determinations of specific proteins 
released from inflammatory cells into the ELF of severely injured patients 
can contribute to elucidate the importance of these cellular products for the 
development of posttraumatic ARDS. 
- Secondly, to examine whether one or more of these biochemical 
inflammation markers can predict the onset as well as the severity of a 
posttraumatic ARDS course. 
To achieve these aims, three neutrophil lysosomal proteins — elastase, 
myeloperoxidase, and lactoferrin — as well as the macrophage-derived pro-
teinase cathepsin B , the fibroblast product P-III-P, and the proteinase 
inhibitor a{?\ were determined in B A L fluid samples drawn daily from 
multiply injured patients over a generally 14 days posttraumatic observation 
period. 
Methods 
Study Population 
Multiply injured patients (rc = 27; Injury Severity Score >40 points) from two 
surgical centers (17 subjects from Essen, 10 from Hannover) were included in 
this study with a prospectively fixed observation period of 14 days. The 
persistent rise of extravascular lung water ( E V L W ) to above 10 ml/kg body 
weight about 3-4 days after admission was taken as a reliable sign of an 
increase in pulmonary microvascular permeability. According to this feature, 
12 patients had to be classified as " A R D S ' ' subjects, the other 15 as a "non-
A R D S " group [16]. Two of the ARDS patients died within 8 days, and three 
individuals 12 days post trauma, whereas the three nonsurviving patients in 
the non-ARDS collective died on the 9th and 12th and after the 14th post-
traumatic day, respectively. 
In addition, ten healthy subjects served as controls for comparative 
measurements of the test parameters. 
Sampling Procedure 
Bronchoalveolar Lavage Fluid (BALF). To obtain ELF from the alveoli, 
B A L was performed by instilling 100 ml 0.9% saline in 20-ml aliquots via a 
fiberoptic bronchoscope as described previously [15, 16]. In about half of the 
traumatized patients, this procedure was carried out daily, whereas due to 
logistic conditions in the other injured patients, performance of B A L was 
feasible only every 2nd day up to the patient's death or the end of the 14-day 
observation period. The healthy individuals were subjected to one BA.L each 
on three successive days [15]. 
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After withdrawal (recovery of more than 60% of the instilled saline), 
cellular components and fluid phase of the combined lavage suspensions were 
immediately separated by centrifugation [15, 16]. The unconcentrated B A L F 
(on average containing more than 60-fold diluted ELF) was then kept frozen 
at —70°C until determination of specific proteins and urea. 
Citrated Plasma. A t each performance of B A L , venous blood was drawn 
simultaneously from a central line, processed to citrated plasma and deep-
frozen at — 70°C until selected plasma components had been assayed. 
Protein Determinations 
The neutrophil lysosomal proteins elastase (complexed with a]PI), myelo­
peroxidase, and lactoferrin in B A L F and plasma samples were determined 
by specific enzyme-linked immunoassays (established in the Biochemical 
Department of E. Merck, Darmstadt, FRG) as indicated elsewhere [14]. 
To quantify proteolytically active neutrophil elastase in B A L F , one part 
of each B A L F sample was incubated with normal plasma containing enough 
o^PI for total elastase inhibition and then reassayed for an increase in the 
elas tase-α^ΡΙ complex. After subtracting the amount of the complex added 
with the normal plasma and correcting for the dilution effect, a rise of more 
than 10% in elastase-atPI complex over the complex concentration already 
present in the untreated portion of the same B A L F sample was taken as 
reliable proof for the occurrence of proteolytically active elastase in the 
alveolar epithelial environment. 
The macrophage-derived lysosomal cysteine proteinase cathepsin Β was 
quantified only in pilot measurements as described by Assfalg-Machleidt 
et al. [2] by estimating the enzyme-catalyzed cleavage of a convenient 
fluorogenic substrate. 
Determination of the fibroblast product P-III-P was carried out with a 
commercially available radioimmunoassay (RIA-gnost Prokollagen-III-
Peptid, Behringwerke, Marburg, FRG). 
The immunologically detectable amount of c^PI was measured using a 
nephelometric method as described by Dwenger et al. [9]. 
Urea Measurement and Correction of the Dilution Effect in BALF 
Urea concentrations in corresponding B A L F and plasma samples were 
enzymatically determined as described elsewhere [9]. These measurements 
were performed to correct the concentrations of the protein components 
quantified in B A L F samples to their original amount in the ELF. Since it is 
suspected that urea diffuses without restriction between the blood/air 
compartments of the lung, the ratio of the urea concentration between blood 
and B A L F is supposed to indicate the dilution of ELF by saline. According to 
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Rennard et al. [23] the following calculation was applied to evaluate 
concentrations (C) of various proteins in ELF: 
c ' · τ—ιf τ—ι
 c protein in B A L F x c urea in plasma 
^protein in ELF = ρ : —^ A τ ^ 
v c urea in B A L F 
Diagrams 
Data are presented as follow-up curves, either for an individual subject or as 
mean ± SEM for the two study groups (ARDS; non-ARDS) if not otherwise 
stated. 
Statistical analysis was performed using the Mann-Whitney U-test. 
Results 
BALF Data of Healthy Subjects 
B A L repeated daily in healthy subjects triggered a distinct influx of PMN 
granulocytes (mean number of cells/ml B A L F was 5700 in the first lavage and 
27600 in the third lavage) to the alveolar space and a significant release of 
lysosomal proteins, which indicated local neutrophil activation. This was 
confirmed not only by the increase in extracellular complexed elastase from 
an average concentration of 0.77μg/ml ELF (first B A L ) (range: 0.37-1.0) up 
to 4 ^ g / m l ELF (third B A L ) (range: 2.2-6.9), but also by the rise in the 
specific amount of the elastase complex from 4.8 ng up to 10.4 ng/1000 PMN 
cells. Yet, no proteolytically active elastase could be demonstrated in any of 
these B A L F samples. Remarkably, the concentration of complexed elastase 
in the E L F of healthy subjects was approximately tenfold that of normal 
plasma levels (80 ng/ml) 
The lysosomal neutrophil proteins, myeloperoxidase and lactoferrin, 
were discharged in a similar manner, although in a somewhat lower amount in 
the case of myeloperoxidase (up to 4.2μg/ml ELF in the third B A L ) and a 
clearly higher amount in the case of lactoferrin (up to l7.2μg/ml E L F in the 
third B A L ) than elastase. Since the release of such quantities of neutrophil 
proteins did not entail any pathological pulmonary disturbances (e.g., influx 
of blood proteins) in the volunteers, an extracellular concentration of 7μg 
complexed elastase or myeloperoxidase as well as 20 μg lactoferrin/ml ELF 
might be suggested as the upper physiologically tolerable l imit . 
The average immunologically determined concentration of 200μg/ml 
ELF of the main elastase inhibitor, c^PI, corresponds to about 10% of the 
plasma level. This level did not change during repeated B A L procedures, 
thus indicating the absence of an increase in pulmonary permeability. 
Interestingly, this inhibitor amount equals maximally to only about a 140-fold 
molar excess over the extracellular concentration of the elastase measurable 
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in the ELF under physiological conditions, whereas in the plasma of healthy 
subjects, it is more than 10000-fold. 
With the assay system applied (lower detection limit: 1 ng/ml) no P-III-P 
could be demonstrated in the B A L F samples of the healthy volunteers. 
Due to logistic conditions, B A L F samples had not been available for the 
evaluation of normal values of the macrophage proteinase cathepsin Β in the 
ELF. 
BALF Data of Traumatized Patients 
As shown in Fig. 1, a repeated release of elastase (measured as the total 
amount of complexed elastase after the addition of inhibitorily active a!PI) up 
to more than 60-fold normal values could be seen in all patients during the 
whole observation period, with a tendency to larger amounts on days 4 -6 
post trauma. This period was generally associated with the manifestation of 
the increase in the amount of E V L W in the ARDS group. Surprisingly, 
however, the neutrophil proteinase was discharged to an even higher, though 
not statistically different, degree in the non-ARDS patients. The same held 
pg/ml 
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20 
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* * * * • ·· · · * ·* 
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Fig. 1. Posttraumatic course of the overall released neutrophil elastase (E) , measured as 
E - a j P I complex after the addition of inhibitorily active arproteinase inhibitor (ct|PI) to 
the alveolar epithelial lining fluids ( E L F ) of ARDS (solid line; asterisk; η ^ 12) and 
non-ARDS (broken line; circle; η =S 15) patients. Data are given as individual 
measurements in the early, and as mean ± SEM in the later posttraumatic phase 
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Ί «284 
hours days 
Fig. 2. Posttraumatic course of neutrophil lactoferrin in the alveolar epithelial lining fluids 
( E L F ) of ARDS (solid line; asterisk; η ^ 7) and non-ARDS (broken line; circle; η ^ 10) 
patients. Data are given as individual measurements in the early, and as mean ± SEM in 
the later posttraumatic phase 
true for myeloperoxidase (not depicted here) and lactoferrin (Fig. 2). The 
simultaneous release of all three lysosomal proteins, especially during the 
manifest elevation of E V L W , is exemplarily shown in Fig. 3. The data are 
from a patient who finally overcame the ARDS phase. 
Sequential mean ct|PI concentrations were distinctly more elevated above 
normal in the ELF of the ARDS collective (on an average between 600 and 
1200μg/ml) than in the non-ARDS group who generally showed a 1.5- to 
3-fold (300-600μg/ml) increase (Fig. 4). Despite scarce data available for 
the first 48 h post trauma, o^PI concentrations well above 300μg/ml ELF in 6 
of 12 ARDS patients and 2 of 15 non-ARDS patients indicate a very early 
trauma-induced pulmonary capillary permeability leakage which was clearly 
more pronounced in the ARDS group. This is confirmed by the observation 
that during the early posttraumatic phase, a,PI in the ELF of ARDS patients 
reached concentrations which were already as high as in the later course of 
the disease. In contrast, the plasma levels of a!PI were clearly lower at the 
beginning of the observation period (below 2000μg/ml) and increased up to 
fivefold (to approximately 6(XK^g/ml) within 6 days after the traumatic 
event (Fig. 5; in the graphs, the plasma α^ΡΙ levels of traumatized 
patients not subjected to B A L for clinical reasons are also included). 
Assuming that with an intact blood/air barrier the influx of a!PI to the 
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Posttraumatic courses 
of neutrophil a 
complexed elastase 
(Ε -α,ΡΙ) , 
b myeloperoxidase 
(MPO), and c 
lactoferrin (LF) in the 
alveolar epithelial 
lining fluids ( E L F ; 
solid line) and the 
bronchoalveolar 
lavage fluids (BALF; 
broken line) of an 
ARDS patient, 
d ARDS is indicated by 
the manifest elevation 
in extravascular lung 
water ( E V L W ) above 
10 ml/kg body weight 
between the fifth and 
ninth posttraumatic 
day 
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Fig . 4. Posttraumatic course of α,-proteinase inhibitor (a,PI) in the alveolar epithelial 
lining fluids ( E L F ) of ARDS (solid line; asterisk; η ^ 12) and non-ARDS (broken line; 
circle; η ^ 15) patients. Data are given as individual measurements in the early, and as 
mean ± SEM in the later posttraumatic phase. 
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Fig. 5. Posttraumatic course of arproteinase inhibitor (a,PI) in plasma samples of ARDS 
(solid line; η =S 26) and non-ARDS (broken line; η ^ 31) patients. Data (including those of 
patients not subjected to bronchoalveolar lavage for clinical reasons) are given as mean ± 
pseudoStandard error (PSE). Asterisks mark significant differences between the two patient 
groups (p < 0.05) 
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alveolar epithelial compartment approaches at most 10% of the blood level, 
an early and/or late pulmonary permeability increase could be seen in 11 of 
the 12 ARDS patients, whereas such a disturbance could be verified only in 3 
of the 15 non-ARDS subjects. 
Taking 300 μg c^PI/ml ELF - if reached within 48h post trauma - as a 
threshold level for the prognosis of later ARDS, the following predictive 
parameters were calculated: 63% for sensivity, 7 1 % for specificity, 80% for 
the positive predictive value, and 58% for the negative predictive value. 
Although the immunologically measurable o^PI concentration was highly 
elevated in the E L F of ARDS patients, the molar excess of α Γ ΡΙ over the total 
amount of released elastase varied generally in the later posttraumatic phase 
only between 8.6- to 39.6-fold (Fig. 6) compared with about 140-fold under 
normal conditions. This reduced ratio does not seem to be enough to 
inactivate the whole amount of elastase discharged from the stimulated 
invading neutrophils. As shown in Fig. 7a, up to 30% of the released elastase 
could be detected as an active enzyme in the ARDS group. Moreover, due to 
the lower amount of c^PI in the ELF of non-ARDS subjects and the clearly 
Fig. 6. Posttraumatic course of the calculated molar ratio of α,-proteinase inhibitor to the 
overall released neutrophil elastase (see Fig. 1) in alveolar epithelial lining fluids ( E L F ) of 
12 ARDS (solid line; asterisk) and 15 non-ARDS (broken line; circle) patients. In the E L F 
of healthy subjects this ratio is approximately 140-fold. Data are given as individual ratios 
in the early, and as ratio of mean values in the later posttraumatic phase 
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Fig. 7a,b. Posttraumatic courses of overall released neutrophil elastase (Ε-α,ΡΙ; see Fig. 
1.), proteolytically active elastase (free E) and a,-proteinase inhibitor (a,PI) in the alveolar 
epithelial lining fluids ( E L F ) . Data are given as means for a 12 ARDS patients and b 15 
non-ARDS patients in the later posttraumatic phase 
higher release rate of elastase especially in the later posttraumatic phase, the 
molar surplus of cijPI in these subjects was only 1.9- to 12.8-fold (Fig. 6). This 
might be responsible for the observation that, on average, more than 50% of 
the extracellular neutrophil proteinases were not inhibited by the locally 
available epithelial c^PI (Fig. 7b) in the non-ARDS collective. 
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Fig. 8a,b. Individual posttraumatic courses of overall released neutrophil elastase mea­
sured as Ε-α,ΡΙ complex and macrophage-derived cathepsin Β in the bronchoalveolar 
lavage fluids (BALF) of individual patients, a Pat. 429 without ARDS, and b Pat. 431 with 
ARDS 
Due to logistic conditions, the release of the alveolar macrophage-
derived cysteine proteinase cathepsin Β could be determined only in pilot 
measurements. Fig. 8 depicts the discharge pattern of cathepsin Β compared 
with that of neutrophil elastase in the B A L F of a non-ARDS (Pat. 429) and 
an ARDS subject (Pat. 431), respectively. Both proteinases showed a re-
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Fig 9. Individual 
P-III-P posttraumatic courses of 
the procollagen-III-
peptide (P-III-P) in the 
alveolar epithelial lining 
fluids ( E L F ) of four 
ARDS patients. Three 
patients (+) did not 
survive the organ failure 
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peated, though not congruent, release which indicates more or less 
permanent posttraumatic activation of the phagocytic cells. In contrast to the 
above-given elastase data (combined in mean values for each study group), 
the diagrams of the individual patient's data point to a distinctly lower 
stimulation of both types of phagocytes in the non-ARDS subject. 
For measuring the fibrosis marker P-III-P, sequential B A L F samples had 
been available only from a subgroup of the study population (6 ARDS and 
7 non-ARDS subjects from Essen). Up to the 4th posttraumatic day, P-III-P 
was not elevated above the lower detection limit (1 ng/ml) of the applied 
assay in any of the B A L F specimens. Between the 4th and 9th posttraumatic 
days, P-III-P started to increase in all ARDS patients reaching maximum 
values of 2.2-4.9 μg/ml ELF. Because of the small number of and great 
individual variation in the data, it is not feasible to present these as mean 
values. Therefore, four separate diagrams are depicted in Fig. 9. In contrast 
to the high and longer lasting (more than 5 days) elevation of P-III-P in all 
ARDS subjects, in 4 of the 7 non-ARDS patients, no P-III-P could be 
detected in any of the B A L F samples drawn daily during the whole observa­
tion period. The other three subjects exhibited only a short-term (2-3 days) 
slight P-III-P increase (maximum values: 0.2-0.6 μg/ml ELF) in the late 
posttraumatic phase. Although P-III-P levels above 1 μg/mg ELF were always 
associated with A R D S , they did not predict the outcome of the disease. 
Discussion 
In the present study, we intended to contribute to the understanding of the 
ambiguous role of PMN granulocytes in the pathogenesis of ARDS by 
measuring extracellularly released neutrophil proteins in B A L F samples 
drawn daily from polytraumatized high-risk patients. The conversion of the 
protein concentrations quantified in B A L F to the actual amounts present in 
alveolar ELF by using the plasma/BALF concentration ratio of urea [23] was 
expected to allow a sufficiently exact follow-up observation of the locally 
discharged neutrophil products. 
Applying this method, in healthy volunteers the amount of neutrophil 
lysosomal constituents, elastase, myeloperoxidase, and lactoferrin, which 
could be determined in ELF, was five- to tenfold the amount found in plasma 
levels measured simultaneously. This may be taken as a clear hint of 
considerable, intensive, local activation of PMN granulocytes, which occurs 
even under physiological conditions. Although repeated B A L was associated 
with an increased alveolar influx and stimulation of neutrophils, the quantity 
of proteolytically and oxidatively active cell products released thereby did not 
apparently disturb the blood/air barrier. Likewise, the amount of c^PI, 
though only available in a 140-fold molar surplus over elastase as compared to 
a more than 10000-fold excess in plasma, seemed to be enough to achieve 
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complete inactivation of its discharged target enzyme. From the given results 
we may conclude that concentrations up to 7 μg complexed elastase/ml ELF 
are without pathophysiological relevance. 
Moreover, taking the rise in E V L W as an unequivocal sign of ARDS 
[16], it became obvious in our study that even neutrophil movement into the 
airspaces of patients at high risk did not necessarily cause an increase in 
alveolar capillary membrane permeability. Although these results are in 
agreement with those reported by others [21], some paradoxical phe­
nomenon shown here deserve further explanation. 
As outlined, the amounts of neutrophil lysosomal proteins repeatedly 
discharged into the ELF of non-ARDS patients were distinctly higher than 
those in A R D S subjects, whereas in the latter cases the local plasma-derived 
o^PI was clearly elevated, especially in the early posttraumatic phase. 
Considering the recent findings of Dwenger et al. and Zilow et al. (see this 
volume), this discrepancy may be explained as follows. The severe traumatic 
event triggered the influx of neutrophils to the alveolar environment of all 
patients at risk to develop ARDS. During adhesion to the endothelial layer 
and the subsequent passage through the alveolar capillary barrier, the cells of 
patients who eventually developed ARDS could have been considerably 
more activated, probably by the neutrophil-stimulating complement compo­
nents, C3a and C5a, which were present in clearly augmented amounts in the 
circulation of such patients. 
Thereby, the aggressive neutrophil substances, which were also released 
in higher quantities into the circulation, may have contributed to the more or 
less simultaneous destruction of the pulmonary endothelial and epithelial cell 
layer, giving rise to increased permeability not necessarily associated with an 
elevation in E V L W . This early disturbance of the blood/air barrier is, 
however, reflected by the significantly higher ELF concentrations of 
plasma-derived a,PI found in ARDS patients than those found in non-ARDS 
patients and healthy volunteers. 
Since preactivated neutrophils, which had invaded the epithelial compart­
ment, had evidently exhausted their lysosomal protein equipment, they may 
have responded to supplementary local stimuli (bacteria, cell debris, 
complement split products, etc.) only with a diminished release of cellular 
constituents. In addition, in the later posttraumatic course a growing portion 
of immature granulocytes with a distinctly lower content of lysosomal 
proteins appeared in the circulation of ARDS patients and was stimulated to 
pass the alveolar capillary barrier. This altogether may have been responsible 
for the generally lower amount of neutrophil proteins present in ELF of 
ARDS than in that of non-ARDS subjects. 
In the later course of ARDS (from the 4th posttraumatic day onwards) 
the epithelial wall seemed to be sealed again by fibrotic processes, as is partly 
demonstrated by the appearance of the fibroblast product P-III-P in ELF 
specimens, whereas the endothelial layer continued to be progessively 
destroyed. This pathological situation was now associated with a manifest 
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increase in E V L W in the ARDS patients. Despite reparative processes on the 
epithelial side of the alveoli, the repeated influx of plasma-derived a!PI well 
above the regular 10% ELF/plasma ratio of this protein can be taken as a 
further indication that the blood/air barrier was still disturbed. 
In contrast, in non-ARDS subjects a similar permanent pulmonary 
impairment could not be verified, neither by a persistent influx of αjPI nor by 
the rise in E V L W . Here, an early transitory inflow of o^PI into the alveolar 
space distinctly exceeding the physiological 10% ELF/plasma ratio was 
followed later by a two- to threefold elevation in ELF-a ( PI , which can be 
explained by the simultaneously rising plasma concentration of the inhibitor 
as an acute phase protein. 
Although the o^PI concentration was far above the normal value in all 
E L F specimens of the traumatized patients, this was apparently not sufficient 
to inhibit all neutrophil elastase released in the local epithelial milieu of the 
alveoli. Therefore, the obviously deficient inhibitory capacity of ajPI may 
have been caused by two synergic effects. On the one hand, despite the 
increase of c^PI in ELF, the inhibitor amount equalled only a considerably 
lower molar surplus (in general two- to 40-fold) over its released target 
enzyme compared to the 140-fold excess found under physiological condi­
tions. This by itself might give rise to a locally incomplete proteinase 
inhibition. On the other hand, the simultaneously discharged neutrophil 
lysosomal proteins myeloperoxidase and lactoferrin - both of which are 
known to be involved in oxidatively destructive processes [18, 17] - as well as 
the macrophage-derived cathepsin B , presumably together with the even 
more potent c^PI-degrading cathepsin L and metalloproteinases (for refer­
ences see [8]), may have contributed to an additional decrease in the elastase 
inhibitory capacity, which was not previously sufficient. Applying special 
assay systems, both oxidatively and proteolytically inactivated ayFl could be 
demonstrated by Schraufstatter et al. [26] in some individual B A L F samples 
drawn only once during manifest ARDS courses. Moreover, these authors 
also detected active elastase despite the presence of a surplus of immunologi­
cally quantified o^PI in those B A L F specimens. As shown recently, 
proteolytically degraded o^PI is a potent neutrophil chemoattractant [4] and 
may thus augment neutrophil influx to the alveolar spaces, resulting there in 
an increased elastase burden during a pathophysiological situation. However, 
other authors have not been able to demonstrate elastase activity against high 
molecular weight protein substrates in B A L F samples of ARDS patients [33, 
32]. This might be for two reasons: first an insufficiently sensitive assay 
system, which probably did not allow detection of small amounts of free 
elastase in the highly diluted B A L F samples, and second, the lack of enough 
sequentially drawn B A L F specimens during the development and manifesta­
tion of ARDS. As pointed out here, the repeated release of phagocyte 
constituents in to the alveolar space requires a close-meshed sampling 
procedure to enable sufficient insight into the local inflammatory cell-induced 
pathomechanisms. 
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Although the distinctly higher amount of free elastase in the B A L F 
specimens of non-ARDS patients could be due to an augmented local elastase/ 
ci|PI imbalance, these observations seem to contradict the importance which 
is generally assumed for this neutrophil enzyme in the development of 
A R D S . In this respect, our findings support data published by other authors 
(for review of literature see [21]) indicating an equivalent or even higher 
influx and activation of neutrophils in high-risk patients not generating 
A R D S . Yet, it should be kept in mind that both the ARDS and non-ARDS 
patients required artificial ventilation throughout the observation period. 
This indicates persistent lung failure in all severely traumatized subjects. 
Therefore, the considerably higher amounts of neutrophil products released 
to the alveolar compartments of both patient groups may indeed have 
contributed to lung dysfunction in comparison with the situation evaluated in 
healthy volunteers. Moreover, as it can be deduced from the high standard 
deviations of mean, the presentation of data combined in mean values for 
each group may have concealed somehow the individual situation. This is 
exemplarily depicted in Figs. 3 and 8. The diagrams demonstrate the 
existence of a clear correlation between the augmented release of phagocyte 
constituents and elevated E V L W . However, the definition of ARDS as an 
increase of E V L W above 10 ml/kg body weight [16] might not be reliable 
enough to classify exactly the degree of severity of lung function disturbances, 
because those subjects are excluded whose inflammatory cell-induced 
pulmonary dysfunction is already indicated by a smaller elevation in E V L W . 
Therefore, final proof of presumed pathomechanisms awaits further follow-
up studies with higher numbers of a homogeneous (e.g., only traumatized) 
high-risk patients collective, which may allow an exact classification of lung 
dysfunctions according to various clinical and biochemical parameters. 
Regarding the second aim of our study, of the inflammation markers 
measured so far, only (XjPI in amounts above 300μg/nll ELF in the early 
posttraumatic phase heralded the later onset of ARDS with a clinically 
acceptable degree of sensitivity and specificity. These findings are in 
agreement with results published by Fowler et al. [10] who could also show 
permeability changes in patients at high risk for ARDS prior to development 
of the syndrome. Moreover, manifestation of ARDS was clearly confirmed in 
our study by ELF concentrations of the fibrosis parameter P-III-P exceeding 
^ g / m l . Yet, neither this nor the other inflammation markers determined 
here were able to indicate the outcome of the disease. 
Conclusion 
Daily drawn B A L F samples of multiply injured patients and healthy 
volunteers allowed us to confirm a significantly higher influx of neutrophils 
into the alveolar space as well as an increased local discharge of phagocyte 
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(neutrophil; macrophage) constituents (elastase, myeloperoxidase, lacto­
ferrin; cathepsin B) in subjects at high risk to develop ARDS. Hence, these 
aggressive components of inflammatory cells may indeed contribute to the 
occurrence of lung dysfunctions in all severely traumatized patients. 
Taking E V L W elevation above 10 ml/kg body weight as an unambiguous 
sign of ARDS manifestation, in patients showing this sign 3-4 days post 
trauma, the permeability increase of the blood/air barrier was heralded much 
earlier (within 48 h after the traumatic event) by the enhanced inflow of 
plasma-derived a!PI to the alveolar epithelial environment. ELF concentra­
tions of (XiPI above 300μg/ml in this initial posttraumatic phase predicted the 
later occurrence of ARDS with a clinically acceptable degree of sensitivity 
(63%) and specificity (71%). Moreover, concentrations of the fibrosis 
marker, P-III-P, exceeding ^ g / m l E L F confirmed ARDS manifestation. 
However, none of the inflammation markers studied indicated the outcome of 
posttraumatic lung dysfunctions. 
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